Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Improved Stroke Prevention in Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 49:2122-2128, Forslund, T.,et al, 2018
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events
ArchNeurol 57:326-332,306, Hart,R.G.,et al, 2000
Update on Antiplatelet Therapy for Stroke Prevention
Arch Int Med 160:1579-1582, Sacco,R.L.& Elkind,M.S., 2000
A Metaregression Analysis of the Dose-Response Effect of Aspirin on Stroke
Arch Int Med 159:1248-1253, Johnson,E.S.,et al, 1999
Low-Dose and High-Dose Acetylsalicylic Acid for Patients Undergoing Carotid Endarterectomy:A Randomised Controlled Trial
Lancet 353:2179-2184,2172, Taylor,D.W.,et al, 1999
Prospective Study of Aspirin Use and Risk of Stroke in Women
Stroke 30:1764-1771, Iso,H.,et al, 1999
Antiplatelet Therapy:Views from the Experts
Neurol 53:S32-S37, Easton,J.D.,et al, 1999
Aspirin in Ischemic Cerebrovascular Disease-How Strong is the Case for a Different Dosing Regimen
Stroke 27:756-760, Patrono,C.&Roth,G.J., 1996
Aspirin Wars-The Optimal Dose of Aspirin to Prevent Stroke
Stroke 27:585-587, Hart,R.G.&Harrison,M.J.G., 1996
Aspirin Dose in Stroke Prevention-Beautiful Hypotheses Slain by Ugly Facts
Stroke 27:588-592, Barnett,H.J.M.,et al, 1996
Failure of Aspirin Treatment After Stroke
Stroke 25:275-277, Bornstein,N.M.,et al, 1994
Does Low-Dose ASA Prevent Stroke After Carotid Surgery? A Double-blind, Placebo-controlled Randomized Trial
Stroke 24:1125-1128, Lindblad,B.,et al, 1993
Effects of Low-to-High Doses of Aspirin on Platelet Aggregab & Metabol of Thromboxane A2 & Prostacyclin
Stroke 23:1400-1403, Tohgi,H.,et al, 1992
Low-Dose Aspirin and Stroke"It Ain't Necessarily So"
Stroke 23:1395-1399, Dyken,M.L.,et al, 1992
A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg/day) in Pats. After a TIA or Minor Ischemic Stroke
Dutch TIA Trial Study Group, NEJM 325:1261-1266, 1303991., , 1991
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg Aspirin as Secondary Prophylaxis After Cerebrovascular Ischaemic Events
The SALT Coll Group, Lancet 338:1345-13491991., , 1991